Fig. 2: Competing cumulative risks of clearance, progression (to CIN2 + ), and persistence of HPV-16/18 infections in the vaccine and control group. | Nature Communications

Fig. 2: Competing cumulative risks of clearance, progression (to CIN2 + ), and persistence of HPV-16/18 infections in the vaccine and control group.

From: Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years

Fig. 2: Competing cumulative risks of clearance, progression (to CIN2 + ), and persistence of HPV-16/18 infections in the vaccine and control group.

CIN2 + , cervical intraepithelial neoplasia grade 2 or greater; HR-HPV, high-risk human papillomavirus; FDR, false discovery rate. In competing risk analyses, the estimates for progression (to CIN2 + ), clearance, and persistence add up to 100% at each time point. A stratified Benjamini-Hochberg FDR procedure was used to adjust for multiple comparisons. All statistical tests were two-sided, with a significance level of α = 0.05.

Back to article page